Prevention of Murine Sclerodermatous Chronic Graft-Versus-Host Disease by Rapamycin

    Ludovic Belle, Marilène Binsfeld, Sophie Dubois … Frédéric Baron
    Studysummary The authors developed a severe mouse model of chronic graft-versus-host disease and reported that rapamycin treatment improved survival compared to placebo, potentially by promoting regulatory T cell expansion.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on bbmt.org →
    Discuss this study in the Community →